Download Omacor® capsules (post MI)

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Biosimilar wikipedia , lookup

Neuropharmacology wikipedia , lookup

Drug discovery wikipedia , lookup

Pharmacokinetics wikipedia , lookup

Medication wikipedia , lookup

Pharmaceutical industry wikipedia , lookup

Prescription drug prices in the United States wikipedia , lookup

Drug interaction wikipedia , lookup

Pharmacognosy wikipedia , lookup

Prescription costs wikipedia , lookup

National Institute for Health and Care Excellence wikipedia , lookup

Pharmacogenomics wikipedia , lookup

Theralizumab wikipedia , lookup

Bad Pharma wikipedia , lookup

Transcript
22nd May 2012
Omacor® capsules (post MI)
The New Therapies Subgroup discussed the above drug at a meeting on
the 22nd May 2012.The recommendation of this subgroup is as follows:*
The New Therapies Subgroup of the GMMMG considered the therapeutic use
of Omacor® for the secondary prevention of myocardial infarction.
The group does not recommend the use of Omacor® capsules for the
above indication as per NICE CG 172.
The evidence base supporting the use of omacor is derived from the GISSI
Prevenzione study. The trial was published in 1999 and data collection took
place in Italy during the mid to late 90s. During this period, the use of
secondary prevention measures widely used today (e.g. statins, aspirin and
beta-blockers) was much lower. The much lower use of these alternative
secondary prevention measures is likely to have resulted in the trial
overestimating the benefits of Omacor®. In addition the trial had very high
dietary consumption of fish, fresh vegetables and olive oil, described by many
as a ‘Mediterranean diet’ which may also have contributed to the beneficial
effects and so transferability of the results to a Greater Manchester population
are questionable.
The group therefore concluded that a diet high in omega-3 fatty acids should
be encouraged however other secondary prevention measures would be
prioritised over Omacor® for the Greater Manchester population.
Patients should be encouraged to achieve the required level of omega 3 fatty
acids by dietary means.
According to set criteria Omacor® capsules was deemed to be a low priority
for funding.
Review Date May 2017
* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.
▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the
risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug
reactions regardless of the severity of the reaction.
NOT TO BE USED FOR COMMERCIAL OR MARKETING PURPOSES